Recent advances in sequencing technologies and collaborative efforts have led to
substantial progress in identifying the genetic causes of amyotrophic lateral sclerosis (ALS) …

The advancing validation and exploitation of CSF and blood neurofilament light chain
protein as a biomarker of neuroaxonal damage has deeply changed the current diagnostic …

Background The intrathecally administered antisense oligonucleotide tofersen reduces
synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with …

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
affecting upper and lower motor neurons, with death resulting mainly from respiratory failure …

Tofersen (Qalsody™) is an antisense oligonucleotide being developed by Biogen for the
treatment of amyotrophic lateral sclerosis (ALS). On 25 April 2023, tofersen was approved in …

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that
primarily affects motor neurons in the brain and spinal cord. In the recent past, there have …

Interest in amyotrophic lateral sclerosis (ALS) biomarkers has grown exponentially over the
course of the last 25 years, with great hope that they might serve as tools to facilitate the …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
the loss of upper and lower motor neurons. Presently, three FDA-approved drugs are …

Since the discovery of Cu/Zn superoxide dismutase (SOD1) gene mutation, in 1993, as the
first genetic abnormality in amyotrophic lateral sclerosis (ALS), over 50 genes have been …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the
degeneration of motor neurons in the brain and spinal cord. The causes of ALS are not fully …